Varenicline and Inhibitory Control

• Research type

  Research Study

• Full title

  Effect of varenicline on inhibitory control in smokers

• IRAS ID

  34460

• Contact name

  Theodora Duka

• Eudract number

  2009-016093-32

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  Study Examining the Cognitive Actions of Varenicline in Smokers. Varenicline (Champix©) is a medication normally used to help people quit smoking. The success of varenicline as an aid in smokers is thought to be partly due to its ability to reduce craving. In recent years however, research in smokers has revealed that cognitive factors may also be very important (cognition refers to brain mechanisms involved in how we think and remember things). We are therefore carrying out a study that is aimed at investigating whether or not varenicline has cognitive actions in smokers. This is important, as the more we know about successful treatments, the more we can help people who wish to quit smoking. We are looking for healthy volunteers who are smokers to participate in our study. It??s important that anyone who takes part is not considering quitting smoking, as they will need to smoke during the course of the study. The study itself involves taking a single dose of varenicline (the normal therapeutic dose) or placebo (a dummy pill) and then completing some tests of cognition; we expect this to take approximately five hours during a single session. Our study is to be carried out in the Clinical Laboratories at the University of Brighton. It is expected to begin December 2009/January 2010 and be completed by August/September 2011.

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  09/H0304/83

• Date of REC Opinion

  28 Jan 2010

• REC opinion

  Further Information Favourable Opinion